MSD's plan to reduce its headcount by around 6,000, first revealed a couple of weeks ago, looks like it will start at its headquarters in Rahway, New Jersey. Confirmation of that has come in the form ...
Bayer and MSD's hopes of expanding the use of their sGC stimulator Verquvo in heart failure have been dashed by a failed phase 3 trial. The results of the 6,105-patient VICTOR study showed that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback